1mon
TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously.
TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for ...
TG Therapeutics is a prime takeover target, fueled by Briumvi's growth and recent subcutaneous formulation de-risking. Learn why TGTX stock is a buy.
Excellent image quality for small camera. Support for RAW images. Bright rear LCD. Wide range of accessories to build out a full underwater kit. Durable design that's nearly everything-proof. Menu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results